Postchemotherapy resections of residual masses from metastatic non- seminomatous testicular germ cell tumors

Annals of Oncology

Volumn 8, Issue 6, 1997, Pages 531-538

  Hartmann, J T ^a   Schmoll, H J ^b   Kuczyk, M A ^c   Candelaria, M ^a   Bokemeyer, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Metastatic non seminomatous testicular cancer; Outcome analysis; Postchemotherapy residual mass; Predictive factors for histological findings; Secondary surgical intervention

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; GERM CELL TUMOR; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TERATOMA; TESTIS CANCER; TREATMENT OUTCOME;

EID: 0030871931     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008200425854     Document Type: Article

References (44)

1. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-81.
2. Peckham M. Testicular cancer. Rev Oncol 1988; 1: 439-53.
3. Aprikian AG, Herr HW, Bajorin DF et al. Resection of post-chemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994; 74: 1329-34.
4. Wahle GR, Foster RS, Bihrle R et al. Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J Urol 1994; 152: 428-30.
5. Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 1990; 8: 1683-94.
6. Fox EP, Weathers TD, Williams SD et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993; 11: 1294-9.
7. Gelderman WA, Schraffordt-Koops H, Sleijfer DT et al. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol 1988; 38: 227-32.
8. Roth BJ, Greist A, Kubilis PS et al. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up. J Clin Oncol 1988; 6: 1239-47.
9. Einhorn LH, Williams SD, Mandelbaum I et al. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904-8.
10. Geller NL, Bosl GJ, Chan EY. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer 1989; 63: 440-5.
11. Tait D, Peckham MJ, Hendry WF et al. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: The significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984; 50 (5): 601-9.
12. Hendry WF, A'Hern RP, Hetherington JW et al. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit. Br J Urol 1993; 71: 208-13.
13. Jansen RL, Sylvester R, Sleyfer DT et al. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group). Eur J Cancer 1991; 27: 695-8.
14. Fossa SD, Qvist H, Stenwig AE et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992; 10: 569-73.
15. Donohue JP, Rowland RG, Kopecky K et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987; 137: 1176-9.
16. Pugh RCB. Testicular tumours-introduction. In Pugh RCB (ed): Pathology of the Testis. Oxford: Blackwell Scientific Publications 1976; 139-62.
17. Birch R, Williams S, Cone A et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400-7.
18. Einhorn LH, Donohue JP. Combination chemotherapy in disseminated testicular cancer: The Indiana University experience. Semin Oncol 1979; 6: 87-93.
19. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
20. Harstrick A, Schmoll HJ, Kohne-Wompner CH et al. Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol 1991; 2: 197-202.
21. Loehrer PJ Sr, Lauer R, Roth BJ et al. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540 6.
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
23. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B 1972; 34: 187-220.
24. Spiegelhalter DJ. Probabilities prediction in patient management and clinical trials. Stat Med 1986; 5: 421-33.
25. Steyerberg EW, Keizer HJ, Stoter G et al. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: A quantitative overview of 996 resections. Eur J Cancer 1994; 30: 1231-9.
26. Logothetis CJ, Samuels ML, Trindade A et al. The growing teratoma syndrome. Cancer 1982; 50: 1629-35.
27. Molenaar WM, Oosterhuis JW, Meiring A et al. Histology and DNA contents of a secondary malignancy arising in a mature residual lesion six years after chemotherapy for a disseminated nonseminomatous testicular tumor. Cancer 1986; 58: 264-8.
28. Ahlgren AD, Simrell CR, Triche TJ et al. Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy. Cancer 1984; 54: 2015-8.
29. Steyerberg EW, Keizer HJ, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13: 1177 87.
30. Gerl A, Clemm C, Schmeller N et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994; 70: 960 5.
31. Brenner PC, Harry W, Morse MJ et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996; 14: 1765 9.
32. Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumours. Cancer 1986; 57: 978-83.
33. Qvist HL, Fossa SD, Ous S et al. Post-chemotherapy tumour residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol 1991; 145: 300-3.
34. Mandelbaum I, Yaw PB, Einhorn LH et al. The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 1983; 36: 524-8.
35. Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989; 141: 557 9.
36. Mulders PFA, Oosterhoff GON, Boetse C et al. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 1990; 66: 425-9.
37. Gerl A, Clemm C, Schmeller N et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 1995; 6: 483 8.
38. Steyerberg EW, Keizer HJ, Zwartendijk J, et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous tesitcular cancer: A multivariate analysis. Br J Cancer 1993; 68: 195-200.
39. Donohue JP, Fox EP, Williams SD et al. Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: Out-come analysis. World J Urol 1994; 12 (4): 190-5.
40. Harding MJ, Brown IL, MacPherson SG et al. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 1989; 25: 1689 94.
41. Josefsen D, Ous S, Hoie J et al. Salvage treatment in male patients with germ cell tumours. Br J Cancer 1993; 67: 568-72.
42. Peckham MJ, Horwich A, Easton DF, Hendry WF. The management of advanced testicular teratoma. Br J Urol 1988; 62: 63-8.
43. Steyerberg E, Keizer HJ, Messemer JE et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Cancer 1997; 79: 345-55.
44. Stephens WS, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 1637-41.